2054 related articles for article (PubMed ID: 8146331)
21. Construction of X-ray-inducible promoters through cis-acting element elongation and error-prone polymerase chain reaction.
Ogawa R; Lee SI; Kagiya G; Hirano H; Fukuda S; Kondo T; Kodaki T
J Gene Med; 2008 Mar; 10(3):316-24. PubMed ID: 18161064
[TBL] [Abstract][Full Text] [Related]
22. The UV responsive elements in the human mimecan promoter: a functional characterization.
Tasheva ES; Conrad GW
Mol Vis; 2003 Jan; 9():1-9. PubMed ID: 12533723
[TBL] [Abstract][Full Text] [Related]
23. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.
Schewe DM; Leupold JH; Boyd DD; Lengyel ER; Wang H; Gruetzner KU; Schildberg FW; Jauch KW; Allgayer H
Clin Cancer Res; 2003 Jun; 9(6):2267-76. PubMed ID: 12796395
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus-mediated expression and packaging of tissue-type plasminogen activator in megakaryocytic cells.
Chuang JL; Schleef RR
Thromb Haemost; 2001 Jun; 85(6):1079-85. PubMed ID: 11434688
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
26. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
27. Radiation to control transgene expression in tumors.
Marignol L; Coffey M; Hollywood D; Lawler M
Cancer Biol Ther; 2007 Jul; 6(7):1005-12. PubMed ID: 17611403
[TBL] [Abstract][Full Text] [Related]
28. Stable expression of human tissue-type plasminogen activator regulated by beta-actin promoter in three human cell lines: HeLa, WI-38 VA13 and KMS-5.
Morishita H; Nakamura N; Yamakawa T; Ogino H; Kanamori T; Nobuhara M; Namba M
Biochim Biophys Acta; 1991 Oct; 1090(2):216-22. PubMed ID: 1932113
[TBL] [Abstract][Full Text] [Related]
29. Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells.
Boothman DA; Meyers M; Fukunaga N; Lee SW
Proc Natl Acad Sci U S A; 1993 Aug; 90(15):7200-4. PubMed ID: 8346236
[TBL] [Abstract][Full Text] [Related]
30. Modulation of tissue plasminogen activator biosynthesis by phosphatidylinositol liposomes in human fetal lung fibroblasts.
Floru S; Gelvan A; Maran R; Kadouri A; Cohen AM
Am J Hematol; 1991 Feb; 36(2):100-4. PubMed ID: 1707224
[TBL] [Abstract][Full Text] [Related]
31. DANGERS OF X-RAY THERAPY.
Science; 1929 Jul; 70(1803):x. PubMed ID: 17755816
[No Abstract] [Full Text] [Related]
32. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma.
Heaton KM; Sussman JJ; Gershenwald JE; Lee JE; Reintgen DS; Mansfield PF; Ross MI
Ann Surg Oncol; 1998 Jun; 5(4):322-8. PubMed ID: 9641453
[TBL] [Abstract][Full Text] [Related]
33. Role of cytopathology in the diagnosis of ocular malignancies.
Dávila RM; Miranda MC; Smith ME
Acta Cytol; 1998; 42(2):362-6. PubMed ID: 9568136
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of UV-A-induced cytotoxicity to cancer cell lines by camptothecin.
Kojima S; Fujishima H; Wang DS
Anticancer Res; 1997; 17(1A):241-6. PubMed ID: 9066659
[TBL] [Abstract][Full Text] [Related]
35. Surgical treatment of ocular melanoma.
Hungerford JL
Melanoma Res; 1993 Oct; 3(5):305-12. PubMed ID: 8292886
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of cutaneous nevocarcinomas].
Banzet P; Belaich S; Civatte J; Puissant A; Jacquillat C; Israel L
J Chir (Paris); 1976 Mar; 111(3):347-54. PubMed ID: 956292
[TBL] [Abstract][Full Text] [Related]
37. Proteases in cutaneous melanoma.
Ferrier CM; van Muijen GN; Ruiter DJ
Ann Med; 1998 Oct; 30(5):431-42. PubMed ID: 9814829
[TBL] [Abstract][Full Text] [Related]
38. Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein.
Yan C; Han R
Invasion Metastasis; 1997; 17(4):189-98. PubMed ID: 9778591
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic markers, sunlight-related factors and sunscreen use in patients with cutaneous melanoma: an Austrian case-control study.
Wolf P; Quehenberger F; Müllegger R; Stranz B; Kerl H
Melanoma Res; 1998 Aug; 8(4):370-8. PubMed ID: 9764814
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro.
Auzenne E; Leroux ME; Hu M; Pollock RE; Feig B; Klostergaard J
Melanoma Res; 1998 Jun; 8(3):227-39. PubMed ID: 9664144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
